Drug intelligence / Profile preview

AnHorn Medicines Tau degrader

Development stage: Unknown
Lead developer: AnHorn Medicines
Modality: PROTACs (E3 ligase recruitment) → Targeted Protein Degraders (TPDs) → Small Molecules, Bivalent/Multivalent Binders → Multivalent & Scaffold-Based Small Molecules → Small Molecules
Administration: Topical

Overview

AnHorn Medicines is developing a Tau-targeted protein degrader using its proprietary BIGPRO® (Bifunctional Group-driven PROteolysis) platform. This therapeutic candidate is designed to selectively degrade the Tau protein, which is a key driver in the pathogenesis of various tauopathies, including Alzheimer's disease and other neurodegenerative disorders. By utilizing the ubiquitin-proteasome system to eliminate pathological Tau aggregates, the drug aims to halt or reverse disease progression. It is currently in the preclinical stage of development.

Other names: Tau-Targeted protein degradation (BIGPRO®)AnHorn Tau degrader

Targets

MAPT (Microtubule-associated protein tau)

Beyond the preview

Go deeper on AnHorn Medicines Tau degrader.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AnHorn Medicines Tau degrader.

Explore the full profile